Evolus, Inc. (EOLS)
Evolus, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Evolus, Inc. (EOLS) is a Drug Manufacturers - Specialty & Generic company based in US with a market capitalization of $434.3M. Revenue grew 11.6% year-over-year and free cash flow was negative at -$45.7M. This page tracks EOLS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 372 employees · IPO Feb 8, 2018
Valuation
Valuation & price
$6.50as of May 17, 2026· -33.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$434.3M
Market cap
11.6%
Revenue growth (YoY)
64.9%
Gross margin
-$45.7M
Free cash flow (USD)
$101.2M
Net debt
4.0%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 4, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Evolus, Inc.'s market cap?
Evolus, Inc. (EOLS) has a market capitalization of $434.3M.
What is EOLS's P/E ratio?
A meaningful P/E ratio is not available for EOLS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying EOLS stock?
SEC Form 4 filings show no open-market insider buys at Evolus, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Drug Manufacturers - Specialty & Generic
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.